Filgotinib

Filgotinib is an immunology drug developed by Galapagos and licensed to Gilead for the treatment of rheumatoid arthritis. Filgotinib has been evaluated in multiple late-stage clinical studies, demonstrating efficacy and safety. The drug is also being evaluated by Gilead for other autoimmune indications like Crohn’s disease, psoriatic arthritis and ulcerative colitis. Galapagos plans to have greater involvement in European commercialization of Filgotinib and split the development costs with Gilead.